Clinicopathological characteristics and prognosis of multiple-molecular classifier endometrioid adenocarcinoma with POLE mutations
10.12007/j.issn.0258-4646.2025.11.011
- VernacularTitle:POLE突变多重分子特征的子宫内膜样腺癌临床病理特征及预后分析
- Author:
Shan WU
1
;
Jingwei GUO
1
;
Ying ZHANG
1
;
Baoling TIAN
1
;
Zhe WANG
1
Author Information
1. 中国医科大学附属盛京医院病理科,沈阳 110004
- Publication Type:Journal Article
- Keywords:
endometrioid adenocarcinoma;
multiple-molecular classifier;
POLE mutation;
gene sequencing;
p53;
mismatch repair
- From:
Journal of China Medical University
2025;54(11):1023-1028,1035
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinicopathological characteristics and prognosis of multiple-molecular classifier endometrioid adenocarcinomas with DNA polymerase epsilon catalytic subunit(POLE)mutations.Methods In this study,we involved 261 patients with endometrioid adenocarcinoma admitted to the Shengjing Hospital of China Medical University.We detected the expression of the POLE gene and that of p53 protein and mismatch repair(MMR)proteins using gene sequencing and immunohistochemistry,respectively.We analyzed the correlation between different molecular classifications and clinicopathological characteristics using x2 or Fisher test,and Kaplan-Meier survival curves to analyze patients' prognosis.Results We identified nine multiple-molecular classifier cases of endome-trioid adenocarcinoma with POLE mutations,including six POLE mutated+p53 abnormal(POLE mut+p53abn)and three POLE mutated+MMR-deficient(POLE mut+dMMR)cases.Patients with POLE mut+p53abn exhibited significant differences from those with p53abn in terms of the pathological characteristics of tumor-infiltrating lymphocytes and the presence of tumors with peritumoral lymphocyte infiltra-tion(P＜0.05),while no statistically significant difference was present compared to patients with POLE mut(P＞0.05).Kaplan-Meier sur-vival curve analysis revealed that the progression-free survival rates of patients with POLE mut+p53abn and POLE mut+dMMR(100.0％)were higher than those of patients with p53abn(50.0％)and dMMR(8.8％,P＜0.05).Conclusion The clinicopathological characteris-tics of patients with POLE mut+p53abn are similar to those with POLE mut.Both patients with POLE mut+p53abn and POLE mut+dMMR display a good prognosis.
